Top

Published in:

Open Access 01-12-2009 | Research article

Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma

Authors: Hideaki Shimada, Tooru Shiratori, Mari Yasuraoka, Akiko Kagaya, Mari Kuboshima, Fumio Nomura, Masaki Takiguchi, Takenori Ochiai, Hisahiro Matsubara, Takaki Hiwasa

Published in: BMC Cancer | Issue 1/2009

Abstract

Background

Esophageal squamous cell carcinoma (SCC) represents one of the most malignant tumors. To improve the poor prognosis, it is necessary to diagnose esophageal SCC at early stages using new tumor markers. SEREX (serological identification of antigens by recombinant cDNA expression cloning) is suitable for large-scale screening of tumor antigens and has been applied for various types of human tumors.

Methods

Tumor markers of esophageal squamous cell carcinoma (SCC) were screened by SEREX method. The presence of serum anti-makorin 1 (MKRN1) antibodies (s-MKRN1-Abs) was examined by Western blotting using bacterially expressed MKRN1 protein. The expression levels of MKRN1 mRNA in tissues were examined by RT-PCR. The biological activity of MKRN1 was examined by transfection of ras-NIH3T3 mouse fibroblasts with MKRN1 cDNA. Major ubiquitinated proteins in MKRN1-transfected cells were identified by immunoprecipitation with anti-ubiquitin antibody followed by mass spectrometry.

Results

MKRN1 was identified as a novel SEREX antigen of esophageal SCC. Although a total of 18 (25%) of 73 patients with esophageal SCC had s-MKRN1-Abs, none of the 43 healthy donors had a detectable level of s-MKRN1-Abs. There was no correlation between the presence of s-MKRN1-Abs and clinicopathological variables other than histological grading. Well-differentiated tumors were associated significantly with the presence of s-MKRN1-Abs in the patients. The mRNA levels of MKRN1 were frequently higher in esophageal SCC tissues than in the peripheral normal esophageal mucosa. Stable transfection of ras-NIH3T3 cells with MKRN1 cDNA induced prominent morphological changes such as enlargement of the cell body and spreading. Ubiquitination of 80- and 82-kDa proteins were clearly observed in MKRN1-transfected cells but not in the parental cells, which were identified as L-FILIP (filamin A interacting protein 1).

Conclusion

MKRN1 is a novel SEREX antigen of esophageal SCC, and s-NKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC with high specificity. It is plausible that MKRN1 is involved in carcinogenesis of the well-differentiated type of tumors possibly via ubiquitination of L-FILIP.

Available only for authorised users

Isono K, Ochiai T: Recent advances of treatment of cancer of the esophagus (review). Ann Cancer Res Therapy. 1992, 1: 9-16.CrossRef

Daly JM, Karnell LH, Menck HR: National cancer data base report on esophageal carcinoma. Cancer. 1996, 78: 1820-1828. 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z.CrossRefPubMed

Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Itoh H, Ochiai T: Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003, 133: 24-31. 10.1067/msy.2003.31.CrossRefPubMed

Shimada H, Nabeya Y, Okazumi S, Matsubara H, Miyazawa Y, Shiratori T, Hayashi H, Gunji Y, Ochiai T: Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003, 196: 573-578. 10.1016/S1072-7515(02)01905-1.CrossRefPubMed

Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi G, Ochiai T: Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003, 133: 486-494. 10.1067/msy.2003.139.CrossRefPubMed

Foley EJ: Attempts to induce immunity against mammary adenocarcinoma in inbred mice. Cancer Res. 1953, 13: 578-580.PubMed

Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957, 18: 769-778.PubMed

Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995, 92: 11810-11813. 10.1073/pnas.92.25.11810.CrossRefPubMedPubMedCentral

Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997, 94: 1914-1918. 10.1073/pnas.94.5.1914.CrossRefPubMedPubMedCentral

10.

Cancer immunome database. [http://www2.licr.org/CancerImmunomeDB/]

11.

Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000, 89: 1677-1683. 10.1002/1097-0142(20001015)89:8<1677::AID-CNCR5>3.0.CO;2-9.CrossRefPubMed

12.

Shimada H, Nakajima K, Ochiai T, Koide Y, Okazumi S, Matsubara H, Takeda A, Miyazawa Y, Arima M, Isono K: Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers. Oncol Rep. 1998, 5: 871-874.PubMed

13.

Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, Hayashi H, Takeda A, Ochiai T: Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002, 132: 41-47. 10.1067/msy.2002.125307.CrossRefPubMed

14.

Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, Matsubara H, Nomura F, Takiguchi M, Hiwasa T: Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004, 112: 1029-1035. 10.1002/ijc.20517.CrossRefPubMed

15.

Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, Hiwasa T: Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2005, 26: 77-86.PubMed

16.

Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, Hiwasa T, Ochiai T: Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006, 28: 463-468.PubMed

17.

Kuboshima M, Shimada H, Liu T-L, Nomura F, Takiguchi M, Hiwasa T, Ochiai T: Presence of serum TRIM21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006, 97: 380-386. 10.1111/j.1349-7006.2006.00192.x.CrossRefPubMed

18.

Hiwasa T, Shimada H, Ochiai T, Takiguchi M: Serological identification of antigens by recombinant cDNA expression cloning (SEREX) using antibodies from patients with esophageal squamous cell carcinoma. Moleculomics and Thereafter. Edited by: Hiwasa T. 2006, Kerala, India: Research Signpost, 99-117.

19.

Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T, Hiwasa T: Serumanti-myogegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 2007, 30: 97-103.PubMed

20.

Shiratori T, Shimada H, Kagaya A, Kuboshima M, Nabeya Y, Machida T, Goto K, Takiguchi M, Ochiai T, Hiwasa T: Sensitization against anticancer drugs by transfection with UBE2I variant gene into ras-NIH3T3 mouse fibroblasts. Anticancer Res. 2007, 27: 3227-3234.PubMed

21.

Hiwasa T, Shimada H, Kuboshima M, Shiratori T, Kagaya A, Nabeya Y, Sugano S, Ochiai T, Matsubara H, Takiguchi M: Decrease in chemosensitivity against anticancer drugs by an esophageal squamous cell carcinoma SEREX antigen, AISEC. Int J Oncol. 2009, 34: 641-648. 10.3892/ijo_00000189.CrossRefPubMed

22.

Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K: A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T. and T.Tn.). Jpn J Oral Maxillofac Surg. 1990, 36: 307-316.CrossRef

23.

Shimada H, Shimizu T, Ochiai T, Liu TL, Sashiyama H, Nakamura A, Matsubara H, Gunji Y, Kobayashi S, Tagawa M, Sakiyama S, Hiwasa T: Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today. 2001, 31: 597-604. 10.1007/s005950170093.CrossRefPubMed

24.

Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159. 10.1016/0003-2697(87)90021-2.CrossRefPubMed

25.

Sobin LH, Wittekind CH, (Eds): UICC TNM Classification of malignant tumors. 2000, New York: John Wiley & Sons, 6

26.

Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature. 1970, 227: 680-685. 10.1038/227680a0.CrossRefPubMed

27.

Sekiya T, Fushimi M, Mori H, Hirohashi S, Nishimura S, Sugimura T: Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in melanoma from a Japanese patient. Proc Natl Acad Sci U S A. 1998, 81 (15): 4771-4775. 10.1073/pnas.81.15.4771.CrossRef

28.

Hiwasa T, Shimada H, Sakaida T, Kitagawa M, Kuroiwa N, Ochiai T, Takiguchi M: Drug-sensitivity pattern analysis of study of functional relationship between gene products. FEBS Lett. 2003, 552: 177-183. 10.1016/S0014-5793(03)00918-9.CrossRefPubMed

29.

Liu TL, Shimada H, Ochiai T, Shiratori T, Lin S-E, Kitagawa M, Harigaya K, Maki M, Oka M, Abe T, Takiguchi M, Hiwasa T: Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-κB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism. Apoptosis. 2006, 11: 1025-1037. 10.1007/s10495-006-6353-y.CrossRefPubMed

30.

Hiwasa T, Kominami E: Physical association of Ras and cathepsins B and L in the conditioned medium of v-Ha-ras-transformed NIH3T3 cells. Biochem Biophys Res Commun. 1995, 216: 828-834. 10.1006/bbrc.1995.2696.CrossRefPubMed

31.

Gray TA, Hernandez L, Carey AH, Schaldach MA, Smithwick MJ, Rus K, Graves JAM, Stewart CL, Nicholls RD: The ancient source of a distinct gene family encoding proteins featuring RING and C(3)H zinc-finger motifs with abundant expression in developing brain and nervous system. Genomics. 2000, 66: 76-86. 10.1006/geno.2000.6199.CrossRefPubMed

32.

Hirotsune S, Yoshida N, Chen A, Garrett L, Sugiyama F, Takahashi S, Yagami K, Wynshaw-Boris A, Yoshiki A: An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene. Nature. 2003, 423: 91-96. 10.1038/nature01535.CrossRefPubMed

33.

Kim JH, Park S-M, Kang MR, Oh S-Y, Lee TH, Muller MT, Chung IK: Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev. 2005, 19: 776-781. 10.1101/gad.1289405.CrossRefPubMedPubMedCentral

34.

Hiwasa T, Nakata M, Nakata M, Ohno S, Maki M, Suzuki K, Takiguchi M: Regulation of transformed state by calpastatin via PKCε in NIH3T3 mouse fibroblasts. Biochem Biophys Res Commun. 2002, 290: 510-517. 10.1006/bbrc.2001.6197.CrossRefPubMed

35.

Sakiyama S, Hiwasa T: Disorganization of microfilaments caused by tumor promoters in mouse fibroblasts. Gann. 1981, 75 (1): 4-7.

36.

Nagano T, Yoneda T, Hatanaka Y, Kubota C, Murakami F, Sato M: Filamin A-interacting protein (FILIP) regulates cortical cell migration out of the ventiricular zone. Nat Cell Biol. 2002, 4: 495-501.PubMed

37.

Sato M, Nagano T: Involvement of filamin A and filamin A-interacting protein (FILIP) in controlling the start and cell shape of radially migrating cortical neurons. Anat Sci Int. 2005, 80: 19-29. 10.1111/j.1447-073x.2005.00101.x.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/232/prepub

Title: Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma
Authors: Hideaki Shimada
Tooru Shiratori
Mari Yasuraoka
Akiko Kagaya
Mari Kuboshima
Fumio Nomura
Masaki Takiguchi
Takenori Ochiai
Hisahiro Matsubara
Takaki Hiwasa
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-9-232

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Molecular fingerprinting of radiation resistant tumors: Can we apprehend and rehabilitate the suspects?

The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer – a multicenter study

Does the availability of positron emission tomography modify diagnostic strategies for solitary pulmonary nodules? An observational study in France

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy

Array-based DNA methylation profiling of primary lymphomas of the central nervous system

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer